By Connor Hart
Shares of SpringWorks Therapeutics climbed after The Wall Street Journal reported that Germany's Merck KGaA is nearing a $3.5 billion deal for the U.S. biopharmaceutical company.
SpringWorks stock rose 8.7%, to $44.80, in afternoon trading Thursday. Shares are up 2.3% in the past year.
Both companies have agreed on a price close to $47 a share, according to the report, which cited people familiar with the matter. A deal could be completed as soon as Monday, assuming the talks don't hit any more last-minute snags.
German life-sciences and chemicals company Merck in February said it was in advanced talks to buy SpringWorks, after signaling last year that it was on the lookout for deals.
SpringWorks in late 2023 launched its first drug, Ogsiveo, a therapy for desmoid tumors--a rare type of tumor that occurs in connective tissue--in adults. The business had a market value of a little over $3 billion as of Thursday.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
April 24, 2025 15:17 ET (19:17 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。